STAG2-mutated patients’ characteristics
| Variable . | Value . |
|---|---|
| Characteristics and hematologic features of patients with STAG2m | |
| Total no. of patients | 91 |
| Race, n (%) | |
| White | 85 (93) |
| Latino/Hispanic | 4 (4) |
| African American | 1 (1) |
| Other | 1 (1) |
| Sex (male), n (%) | 71 (78) |
| Age (range), y | 72 (25-91) |
| Hemoglobin, median (Q1, Q3), g/dL | 8.7 (7.9, 9.8) |
| Leukocytes, median (Q1, Q3), ×109/L | 2.8 (1.8, 6.0) |
| Platelets, median (Q1, Q3), ×109/L | 88 (36, 129) |
| BM blasts (range), % | 7 (0-86) |
| Circulating blasts (range), % | 3 (0-71) |
| Cytogenetics, n (%) | |
| Abnormal | 28 (31) |
| Normal | 59 (65) |
| Diagnosis, n (%) | |
| MDS | 50 (55) |
| AML | 26 (29) |
| MDS/MPN | 9 (10) |
| MPN | 3 (3) |
| CCUS | 2 (2) |
| Aplastic anemia | 1 (1) |
| t-MN | 14 (15) |
| STAG2m characteristics | |
| VAF of STAG2 (range), % | 50 (5-100) |
| Median VAF, % | |
| Males | 59 |
| Females | 27 |
| AML | 51 |
| MDS | 50 |
| MDS/MPN | 41 |
| MPN | 31 |
| Mutation type, n (%) | |
| Nonsense | 49 (54) |
| Frameshift | 33 (36) |
| Splice site | 9 (10) |
| Comutational pattern | |
| No. of comutations, median (range) | 3 (0-6) |
| Isolated STAG2, n (%) | 6 (7) |
| Major comutations, n (%) | |
| ASXL1 | 59 (65) |
| SRSF2 | 33 (36) |
| TET2 | 33 (36) |
| RUNX1 | 27 (30) |
| BCOR | 18 (20) |
| IDH2 | 16 (18) |
| U2AF1 | 12 (13) |
| Treatment, n (%) | |
| Received at least 1 line of treatment | 64 (70.3) |
| HMA | 30 (47) |
| HMA + VEN | 17 (27) |
| Low-dose cytarabine + VEN | 3 (5) |
| Chemotherapy | 6 (9) |
| TK inhibitor | 4 (6) |
| IDH inhibitor | 1 (2) |
| Immunomodulator | 1 (2) |
| Study therapy | 2 (3) |
| HSCT, n (%) | 25 (28) |
| Variable . | Value . |
|---|---|
| Characteristics and hematologic features of patients with STAG2m | |
| Total no. of patients | 91 |
| Race, n (%) | |
| White | 85 (93) |
| Latino/Hispanic | 4 (4) |
| African American | 1 (1) |
| Other | 1 (1) |
| Sex (male), n (%) | 71 (78) |
| Age (range), y | 72 (25-91) |
| Hemoglobin, median (Q1, Q3), g/dL | 8.7 (7.9, 9.8) |
| Leukocytes, median (Q1, Q3), ×109/L | 2.8 (1.8, 6.0) |
| Platelets, median (Q1, Q3), ×109/L | 88 (36, 129) |
| BM blasts (range), % | 7 (0-86) |
| Circulating blasts (range), % | 3 (0-71) |
| Cytogenetics, n (%) | |
| Abnormal | 28 (31) |
| Normal | 59 (65) |
| Diagnosis, n (%) | |
| MDS | 50 (55) |
| AML | 26 (29) |
| MDS/MPN | 9 (10) |
| MPN | 3 (3) |
| CCUS | 2 (2) |
| Aplastic anemia | 1 (1) |
| t-MN | 14 (15) |
| STAG2m characteristics | |
| VAF of STAG2 (range), % | 50 (5-100) |
| Median VAF, % | |
| Males | 59 |
| Females | 27 |
| AML | 51 |
| MDS | 50 |
| MDS/MPN | 41 |
| MPN | 31 |
| Mutation type, n (%) | |
| Nonsense | 49 (54) |
| Frameshift | 33 (36) |
| Splice site | 9 (10) |
| Comutational pattern | |
| No. of comutations, median (range) | 3 (0-6) |
| Isolated STAG2, n (%) | 6 (7) |
| Major comutations, n (%) | |
| ASXL1 | 59 (65) |
| SRSF2 | 33 (36) |
| TET2 | 33 (36) |
| RUNX1 | 27 (30) |
| BCOR | 18 (20) |
| IDH2 | 16 (18) |
| U2AF1 | 12 (13) |
| Treatment, n (%) | |
| Received at least 1 line of treatment | 64 (70.3) |
| HMA | 30 (47) |
| HMA + VEN | 17 (27) |
| Low-dose cytarabine + VEN | 3 (5) |
| Chemotherapy | 6 (9) |
| TK inhibitor | 4 (6) |
| IDH inhibitor | 1 (2) |
| Immunomodulator | 1 (2) |
| Study therapy | 2 (3) |
| HSCT, n (%) | 25 (28) |
| Response to therapy . | |||
|---|---|---|---|
| . | HMA, n (%) . | HMA + VEN, n (%) . | Chemotherapy, n (%)∗ . |
| CR | 1 (3.8) | 2 (11.8) | 3 (50.0) |
| CRi | 6 (23.1) | 7 (41.2) | 2 (33.3) |
| PR | 0 (0) | 1 (5.9) | 0 (0) |
| HI | 5 (19.2) | 0 (0) | 0 (0) |
| No response | 14 (53.8) | 7 (41.2) | 1 (16.7) |
| Relapse | |||
| Yes | 3 (25) | 6 (60) | 2 (40) |
| No | 9 (75) | 4 (40) | 3 (60) |
| Response to therapy . | |||
|---|---|---|---|
| . | HMA, n (%) . | HMA + VEN, n (%) . | Chemotherapy, n (%)∗ . |
| CR | 1 (3.8) | 2 (11.8) | 3 (50.0) |
| CRi | 6 (23.1) | 7 (41.2) | 2 (33.3) |
| PR | 0 (0) | 1 (5.9) | 0 (0) |
| HI | 5 (19.2) | 0 (0) | 0 (0) |
| No response | 14 (53.8) | 7 (41.2) | 1 (16.7) |
| Relapse | |||
| Yes | 3 (25) | 6 (60) | 2 (40) |
| No | 9 (75) | 4 (40) | 3 (60) |
CCUS, clonal cytopenia of unknown significance; CR, complete remission; CRi, complete remission with incomplete hematologic recovery; HI, hematologic improvement; IDH, isocitrate dehydrogenase; PR, partial response; TK inhibitor, tyrosine kinase inhibitor; VEN, venetoclax.
Chemotherapy regimens used were 7 + 3 with or without midostaurin.